Last reviewed · How we verify
Lenalidomide and low-dose dexamethasone
Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth.
Lenalidomide enhances immune cell activity and has anti-angiogenic and anti-proliferative effects, while dexamethasone provides anti-inflammatory and immunosuppressive activity to reduce myeloma cell growth. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Light chain myeloma.
At a glance
| Generic name | Lenalidomide and low-dose dexamethasone |
|---|---|
| Also known as | Revlimid |
| Sponsor | Celgene |
| Drug class | Immunomodulatory agent + corticosteroid |
| Target | Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory agent that activates T cells and natural killer cells, inhibits angiogenesis, and directly suppresses myeloma cell proliferation. Dexamethasone, a corticosteroid, enhances these effects through anti-inflammatory mechanisms and direct cytotoxic activity against plasma cells. The combination is synergistic in treating multiple myeloma.
Approved indications
- Multiple myeloma (newly diagnosed and relapsed/refractory)
- Light chain myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Constipation
- Neuropathy
- Infection
- Hyperglycemia
- Insomnia
- Venous thromboembolism
Key clinical trials
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- A Study of Ninlaro in Real World Clinical Practice in China
- Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma (PHASE2)
- MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma (PHASE1)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma (PHASE3)
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma (PHASE2)
- Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lenalidomide and low-dose dexamethasone CI brief — competitive landscape report
- Lenalidomide and low-dose dexamethasone updates RSS · CI watch RSS
- Celgene portfolio CI